Avalyn Pharma
AVLN
25.53
+0.10
+0.39%
Avalyn Pharma
US · AVLN
#3161 by market cap
Listed 2026
25.53
+0.10
+0.39%
Live - 5344 symbols - heartbeat 127s ago
· 2026-10-08 04:12
Pre-market
25.98
+1.74%
After-hours
25.53
0.00%
- Market cap
- 1.13B
- P/E (TTM)i
- -10.96
- P/Bi
- 2.84
- EPSi
- -2.04
- Div yieldi
- 0.00%
- 52W posi
- 9%
Reader sentiment
Are you bullish or bearish on AVLN?
Anonymous reader poll. Unscientific, not investment advice.
About Avalyn Pharma
Avalyn Pharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). The company was founded by Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar on May 27, 2011 and is headquartered in Boston, MA.
- Founded
- 2011
- CEO
- Ms. Lyn Baranowski
- Employees
- 51
- Headquarters
- Boston, Massachusetts, United States of America
- Fiscal year end
- 12-31
- Website
- avalynpharma.com
Company profile
- Exchange
- US
- Symbol
- AVLN
- Market-cap rank
- #3161
- Listing date
- 2026-04-30
- Market cap
- 1.13B
- Float cap
- 425.50M
- Shares out
- 44.33M
- Float shares
- 16.67M
Sectors & themes
Biotechnology
IPOs
Quote time 2026-10-08 04:12:40 · For reference only, not investment advice and not tailored to your situation.